公开(公告)号：US11773150B2

公开(公告)日：2023-10-03

申请号：US17004395

申请日：2020-08-27

申请人： Merck Sharp & Dohme LLC ,  Ambrx, Inc.

发明人： Paul E. Carrington ,  Grigori Ermakov ,  Robert M. Garbaccio ,  Wolfgang Seghezzi ,  Elisabetta Bianchi ,  Federica Orvieto ,  Dennis Gately ,  Nick Knudsen ,  Anthony Manibusan

IPC分类号： C07K14/605 ,  C07K16/26 ,  C07K16/28 ,  A61K47/68 ,  A61P3/10 ,  A61K39/00

CPC分类号： C07K14/605 ,  A61K47/6811 ,  A61K47/6843 ,  A61P3/10 ,  C07K16/26 ,  C07K16/2869 ,  A61K2039/505 ,  C07K2317/75 ,  C07K2319/00

摘要： Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

公开(公告)号：US20230257460A1

公开(公告)日：2023-08-17

申请号：US18006169

申请日：2021-08-03

申请人： Eli Lilly and Company

发明人： Petra VERDINO ,  Hsiu-Chiung YANG

IPC分类号： C07K16/26 ,  C12N5/00 ,  C12N15/85

CPC分类号： C07K16/26 ,  C12N5/00 ,  C12N15/85 ,  C07K2317/21 ,  C07K2317/92 ,  C12N2800/107

摘要： The present invention provides compounds and methods targeting insulin-like peptide-5 (INSL5), including antibodies, cells and vectors comprising DNA encoding the same, and methods for producing the antibodies. In addition, the present invention provides for use of INSL5 antibodies in diagnostic assays.

公开(公告)号：US20230250160A1

公开(公告)日：2023-08-10

申请号：US17997270

申请日：2021-04-29

申请人： Hober Biotech AB

发明人： Sophia Hober ,  Sarah Lindbo ,  Emma von Witting

IPC分类号： C07K16/18 ,  C07K16/24 ,  C07K16/30 ,  C07K16/28 ,  C07K16/22 ,  C07K16/26 ,  A61K39/395 ,  A61K51/00 ,  A61K31/7048

CPC分类号： C07K16/18 ,  C07K16/241 ,  C07K16/3069 ,  C07K16/2818 ,  C07K16/22 ,  C07K16/26 ,  A61K39/3955 ,  A61K51/00 ,  A61K31/7048 ,  C07K2317/31

摘要： The present disclosure provides for a bispecific protein that enables simultaneous binding of both albumin and a desired target to an ADAPT (ABD Derived Affinity ProTeins) molecule. The present disclosure provides for an ADAPT molecule wherein the proposed binding surface of the desired target is located on helix 1 and helix 2 of the ADAPT molecule.

公开(公告)号：US11712470B2

公开(公告)日：2023-08-01

申请号：US16951913

申请日：2020-11-18

申请人： GMAX BIOPHARM LLC

发明人： Cheng Zhang ,  Hua Zhang ,  Xiaofeng Wang ,  Chenjiang Yao ,  Yan Jiang ,  Min Wang ,  Xinxin Shi ,  Hao Pan ,  Shuqian Jing

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/26 ,  C12N5/10 ,  C12N5/12 ,  C12N15/63 ,  A61P9/00 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K39/39558 ,  C07K16/26 ,  C07K16/28 ,  C12N5/10 ,  C12N5/12 ,  C12N15/63 ,  A61K2039/505 ,  A61P9/00 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

公开(公告)号：US20230212281A1

公开(公告)日：2023-07-06

申请号：US17815749

申请日：2022-07-28

申请人： Cephalon, LLC

发明人： Anthony Gerard DOYLE ,  Adam CLARKE ,  Danyal BUTT ,  David LAINE ,  Hugh MACRAE ,  Jenny VO ,  Julia ROZENFELD ,  Sachin SURADE

IPC分类号： C07K16/26

CPC分类号： C07K16/26 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/565 ,  C07K2317/567

摘要： The present disclosure generally relates to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

公开(公告)号：US20230168258A1

公开(公告)日：2023-06-01

申请号：US17995125

申请日：2021-03-30

申请人： UNIVERSIDAD DE MURCIA

发明人： José Joaquín CERÓN MADRIGAL ,  Silvia MARTÍNEZ SUBIELA ,  Marina LÓPEZ ARJONA

IPC分类号： G01N33/74 ,  C07K16/26

CPC分类号： G01N33/74 ,  C07K16/26 ,  C07K2317/565

摘要： The present invention relates to an in vitro method for the quantification of free oxytocin, protein-bound oxytocin that can be released in a reduction/alkylation treatment, and protein-bound oxytocin, in a sample, without performing a reduction/alkylation treatment, wherein said method comprising carrying out a first assay using a monoclonal antibody that binds specifically to free oxytocin and to protein-bound oxytocin that can be released in a reduction/alkylation treatment, and carrying out a second assay using a polyclonal antibody that binds specifically to protein-bound oxytocin. The invention also relates to the monoclonal antibody and polyclonal antibody, and to a composition and kit comprising same.

公开(公告)号：US11644468B2

公开(公告)日：2023-05-09

申请号：US16498557

申请日：2018-03-30

申请人： Progastrine et Cancers S.à r.l.

发明人： Alexandre Prieur

IPC分类号： C07K16/26 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  G01N33/574 ,  C07K16/30 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28

CPC分类号： G01N33/57434 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22 ,  C07K16/26 ,  C07K16/2863 ,  C07K16/3069 ,  G01N33/5748 ,  A61K2039/507 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  G01N2333/96411

摘要： The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

公开(公告)号：US20190218301A1

公开(公告)日：2019-07-18

申请号：US16328935

申请日：2017-08-29

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jesper Gromada ,  Haruka Okamoto ,  Stephen Jaspers ,  Joyce Harp

IPC分类号： C07K16/28 ,  A61P3/10 ,  A61K38/16

CPC分类号： C07K16/2869 ,  A61K38/16 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61P3/10 ,  C07K16/26 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.

公开(公告)号：US20190209681A1

公开(公告)日：2019-07-11

申请号：US16179696

申请日：2018-11-02

申请人： Immuron Limited

发明人： Yaron Ilan ,  Gadi Lalazar ,  Tomer Adar ,  Meir Mizrahi ,  Ami Ben-Ya`acov

IPC分类号： A61K39/395 ,  C07K16/12 ,  C07K16/04 ,  C07K16/26

CPC分类号： A61K39/39508 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/04 ,  C07K16/1232 ,  C07K16/26 ,  C07K2317/12

摘要： The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.

公开(公告)号：US20190135913A1

公开(公告)日：2019-05-09

申请号：US16130166

申请日：2018-09-13

申请人： NOVARTIS AG

发明人： Joy GHOSH ,  Mark Anthony RUTZ ,  Kathrin Ulrike TISSOT-DAGUETTE ,  Igor SPLAWSKI ,  Michael ROGUSKA

IPC分类号： C07K16/26 ,  A61K45/06 ,  A61K39/395 ,  C07K16/22

CPC分类号： C07K16/26 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.